EDAP TMS SA to Announce Fourth Quarter 2021 Financial Results on Wednesday, March 30, 2022

Company to host conference call and webcast on Thursday, March 31, at 8:30 am ET

LYON, France, March 21, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter ended December 31, 2021 after the markets close on Wednesday, March 30, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 31, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, March 31st@ 8:30am Eastern Time
Domestic:                877-451-6152
International:           201-389-0879
Passcode:                13727107
Webcast:                 https://viavid.webcasts.com/starthere.jsp?ei=1529371&tp_key=b54f335485


A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Blandine Confort
Investor Relations / Legal Affairs
+33 4 72 15 31 50

Investor Contact
John Fraunces
LifeSci Advisors, LLC


Primary Logo

Back to news